四烯甲萘醌(Menatetrenone) - 在研适应症：维生素K缺乏性出血，骨质疏松症，出血_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Menaquinone-4、Menatetrenone (JP17/INN)、VITAMIN-MK-4

+ [20]

靶点-

作用机制

骨生成刺激剂

治疗领域

遗传病与畸形内分泌与代谢疾病血液及淋巴系统疾病+ [2]

在研适应症

维生素K缺乏性出血骨质疏松症出血+ [1]

非在研适应症

肝细胞癌绝经期后骨质疏松

原研机构-

在研机构

Sannova KK

Alfresa Pharma Corp.

Eisai Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1972-06-29),

出血低凝血酶原血症

最高研发阶段(中国)无进展

特殊审评孤儿药 (美国)

登录后查看首次获批时间轴

结构

分子式C31H40O2

InChIKeyDKHGMERMDICWDU-GHDNBGIDSA-N

CAS号863-61-6

关联

46

项与四烯甲萘醌相关的临床试验

DRKS00034742 / SuspendedN/AIIT

Vitamin supplementation in cystic fibrosis in the era of modulators: the impact of vitamin K2 on cardio-metabolic health – a randomised double-blind placebo-controlled trial

开始日期2024-08-05

申办/合作机构-

ChiCTR2400081931 / SuspendedN/AIIT

The effect of vitamin K2 fortified nutritional intervention on muscle condition and clinical outcomes in elderly patients with muscle wasting syndrome

开始日期2024-03-19

申办/合作机构-

ChiCTR2400081953 / Recruiting临床1期IIT

A single-arm clinical trial study of the efficacy and safety of vitamin k2 in combination with a second-line standard regimen for the treatment of advanced hepatocellular carcinoma

开始日期2024-03-18

申办/合作机构

青岛大学附属医院

100 项与四烯甲萘醌相关的临床结果

登录后查看更多信息

100 项与四烯甲萘醌相关的转化医学

登录后查看更多信息

100 项与四烯甲萘醌相关的专利（医药）

登录后查看更多信息

1,357

项与四烯甲萘醌相关的文献（医药）

2024-06-25·Clinical chemistry and laboratory medicine

Vitamin D and vitamin K status in postmenopausal women with normal and low bone mineral density

Article

作者: Trifonidi, Ioulia ; Zelzer, Sieglinde ; Enko, Dietmar ; Keppel, Martin ; Chronopoulos, Efstathios ; Tournis, Symeon ; Alonso, Nerea ; Herrmann, Markus ; Meinitzer, Andreas ; Spanou, Loukia ; Markis, Konstantinos

Abstract:

Objectives:

Vitamin D and K are believed to promote bone health, but existing evidence is controversial. This study aimed to measure several metabolites of both vitamins by liquid chromatography tandem mass spectrometry (LC-MS/MS) in a cohort of postmenopausal women with low and normal bone mineral density (BMD).

Methods:

Vitamin metabolites (25-hydroxyvitamin D (25[OH]D), 24,25-dihydroxyvitamin D (24,25(OH)2D), phylloquinone (K1), menaquinone-4 (MK-4) and MK-7) were measured in 131 serum samples by LC-MS/MS. The vitamin D metabolite ratio (VMR) was calculated. Parathyroid hormone (PTH), type I procollagen-N-terminal-peptide (PINP) and C-terminal telopeptides of type I collagen (CTX-I) were measured by immunoassay. Dual X-ray absorptiometry was performed to identify participants with normal (T-score>−1) and low (T-score<−1) BMD.

Results:

Mean age was 58.2±8.5 years. BMD was normal in 68 and low in 63 women. Median (interquartile range) for 25(OH)D and total vitamin K concentrations were 53.5 (39.6–65.9) nmol/L and 1.33 (0.99–2.39) nmol/L. All vitamin metabolites were comparable in individuals with normal and low BMD. Furthermore, BMD and trabecular bone score were comparable in participants with adequate and inadequate vitamin status (at least one criterion was met: 25(OH)D <50 nmol/L, 24,25(OH)2D <3 nmol/L, VMR <4 %, total vitamin K <0.91 nmol/L). PTH, but not PINP or CTX-I, was inversely correlated with 25(OH)D, 24,25(OH)2D and VMR. Synergistic effects between vitamin D and K were not observed.

Conclusions:

Vitamin D and K status is not related to BMD and trabecular bone quality in postmenopausal women. Inverse associations were only seen between vitamin D metabolites and PTH.

2024-02-01·Bioprocess and biosystems engineering

Enhancing menaquinone-7 biosynthesis through strengthening precursor supply and product secretion

Article

作者: Hu, Pengchen ; Peng, Cheng ; Ren, Lujing ; Milon, Ripon Baroi ; Zhang, Bei ; Hu, Xuechao

Menaquinone-7 (MK-7) is an important class of vitamin K2 that is essential in human health and can prevent osteoporosis and cardiovascular disease. However, due to the complex synthesis pathway, the synthesis efficiency is low. The main objective of this study was to explore the effect of enhanced supply of precursors in Bacillus natto. Three precursors of pyruvate, shikimic acid, and sodium glutamate were chosen to investigate the effect of enhanced supply of precursors on MK-7 synthesis. Then, the optimal concentrations, different combinations, and different adding times were systematically studied, respectively. Results showed that the combination of shikimic acid and sodium glutamate could boost MK-7 production by 2 times, reaching 50 mg/L of MK-7 titer and 0.52 mg/(L·h) of MK-7 productivity. Furthermore, adding shikimic acid and sodium glutamate initially and feeding pyruvate at 48 h and 72 h increased MK-7 production to 58 mg/L. At the same time, the expression of the three related genes was also significantly upregulated. Subsequently, a new fermentation strategy combining the precursors enhancement and product secretion was proposed to enhance MK-7 yield and MK-7 productivity to 63 mg/L and 0.45 mg/(L·h). This study proposed a new fermentation regulation strategy for the enhancement of vitamin K2 biosynthesis.

2024-01-01·Free radical biology & medicine

Menaquinone-4 attenuates ferroptosis by upregulating DHODH through activation of SIRT1 after subarachnoid hemorrhage

Article

作者: Zhang, Jiatong ; Ding, Peng-Fei ; Liu, Yang ; Li, Xiao-Jian ; Zhuang, Zong ; Peng, Zheng ; Li, Wei ; Lu, Yue ; Zhu, Qi ; Sheng, Bin ; Hang, Chun-Hua ; Gao, Sen

BACKGROUND:

Menaquinone-4(MK-4), the isoform of vitamin K2 in the brain, exerts neuroprotective effects against a variety of central nervous system disorders. This study aimed to demonstrate the anti-ferroptosis effects of MK-4 in neurons after SAH.

METHODS:

A subarachnoid hemorrhage (SAH) model was prepared by endovascular perforation in mice. In vitro hemoglobin stimulation of primary cortical neurons mimicked SAH. MK-4, Brequinar (BQR, DHODH inhibitor), and Selisistat (SEL, SIRT1 inhibitor) were administered, respectively. Subsequently, WB, immunofluorescence was used to determine protein expression and localization, and transmission electron microscopy was used to observe neuronal mitochondrial structure while other indicators of ferroptosis were measured.

RESULTS:

MK-4 treatment significantly upregulated the protein levels of DHODH; decreased GSH, PTGS2, NOX1, ROS, and restored mitochondrial membrane potential. Meanwhile, MK-4 upregulated the expression of SIRT1 and promoted its entry into the nucleus. BQR or SEL partially abolished the protective effect of MK-4 on, neurologic function, and ferroptosis.

CONCLUSIONS:

Taken together, our results suggest that MK-4 attenuates ferroptosis after SAH by upregulating DHODH through the activation of SIRT1.

11

项与四烯甲萘醌相关的新闻（医药）

2024-01-23

·医药观澜

卫材宣布痛风治疗新药在中国申报上市

▎药明康德内容团队报道1月22日，卫材（Eisai）宣布多替诺雷片新药上市申请已获中国国家药监局药品审评中心（CDE）受理。多替诺雷片（dotinurad）是一款促尿酸排泄药，此前已经于2020年在日本获批用于治疗高尿酸血症和痛风。截图来源：CDE官网痛风是由单钠尿酸盐沉积在关节所致的晶体相关性关节病，目前中国的患病率为1% ~ 3%，并呈逐年上升趋势。痛风除了在急性发作期产生剧烈疼痛，对关节造成损害，还会伴发肾脏病变及其他代谢综合征的表现，如高脂血症、高血压、糖尿病和冠心病等。过高的血尿酸水平（即高尿酸血症）是发生痛风的重要危险因素。据卫材新闻稿介绍，多替诺雷是一种新型痛风治疗药物，通过选择性抑制与肾脏中尿酸重吸收有关的尿酸盐转运蛋白（URAT1），抑制尿酸重吸收并降低血尿酸水平。作为一种URAT1选择性抑制剂，该产品有效抑制肾近端小管URAT1而不影响尿酸排泄因子ABCG2和OAT1/3的功能，相比非选择性URAT1抑制剂降血尿酸的效率更高。公开资料显示，多替诺雷最初由富士药品（FUJI YAKUHIN）研发，卫材于2020年与富士药品达成许可协议，获得该产品在中国的独家开发和销售权。此前在日本开展的一项3期临床研究结果显示，多替诺雷4mg治疗伴或不伴痛风的高尿酸血症患者，58周血尿酸水平≤6mg的患者比例为100%，长期使用对肾功能无明显影响，对肝功能无临床相关影响。在中国，卫材开展了一项旨在评估多替诺雷和非布司他治疗痛风疗效的3期临床研究。该研究纳入451例痛风患者，随机分为多替诺雷4mg组和非布司他40mg组，主要研究终点是治疗24周血尿酸水平≤6.0mg/dL的患者百分比。根据卫材新闻稿，除了治疗痛风的新药多替诺雷，该公司在中国已上市的替普瑞酮胶囊、四烯甲萘醌软胶囊和雷贝拉唑钠肠溶片等药物，在风湿科、肾内科、骨科、内分泌科和心内科等多个领域发挥协同作用。多替诺雷的加入将丰富卫材中国在这些领域的产品管线，惠及广大患者。参考资料：[1]卫材治疗痛风新药「多替诺雷」在中国申报上市. Retrieved Jan 22，2024, From https://mp.weixin.qq.com/s/-X_9_97VxnNsh2xVjsMnlQ[2] 徐东, 等. 中华内科杂志. 2020,59(6):421-426.本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期申请上市临床结果

2024-01-22

·美通社

卫材治疗痛风新药「多替诺雷」在中国申报上市

今日（2024年1月22日），中国国家药品监督管理局药品审评中心（CDE）官网公示，卫材中国以注册分类5.1类申报的多替诺雷片上市申请已获得受理1。多替诺雷片（Dotinurad，商品名：优乐思）是一款促尿酸排泄药，此前已经于2020年在日本上市，用于治疗高尿酸血症和痛风2。痛风是由单钠尿酸盐沉积在关节所致的晶体相关性关节病，目前我国的患病率为1% ~ 3%，并呈逐年上升趋势。痛风除了在急性发作期产生剧烈疼痛，对关节造成损害，还会伴发肾脏病变及其他代谢综合征的表现，如高脂血症、高血压、糖尿病和冠心病等3。过高的血尿酸水平（即高尿酸血症）是发生痛风的最重要的危险因素4。多替诺雷是一种新型痛风治疗药物，通过选择性抑制与肾脏中尿酸重吸收有关的尿酸盐转运蛋白（URAT1），抑制尿酸重吸收并降低血尿酸水平5。作为一种URAT1选择性抑制剂，多替诺雷有效抑制肾近端小管URAT1而不影响尿酸排泄因子ABCG2和OAT1/3的功能，相比非选择性URAT1抑制剂降血尿酸的效率更高2。卫材在中国开展了一项旨在评估多替诺雷和非布司他治疗痛风疗效的3期临床研究（NCT05007392）。该研究纳入451例痛风患者，随机分为多替诺雷 4mg组和非布司他 40mg组，主要研究终点是治疗24周血尿酸水平≤ 6.0 mg/dL的患者百分比6。此前在日本开展的一项3期临床研究结果显示，多替诺雷 4mg治疗伴或不伴痛风的高尿酸血症患者，58周血尿酸水平≤ 6.0 mg/dL的患者达标率100%，长期使用对肾功能无明显影响，对肝功能无临床相关影响7。卫材中国始终将患者利益和公众健康放在首位，满足其多样化需求，为提升其福祉做出贡献。除了治疗痛风的新药多替诺雷，卫材中国已上市的施维舒®（替普瑞酮胶囊）、固力康®（四烯甲萘醌软胶囊）和波利特®（雷贝拉唑钠肠溶片）等多款药物在相关领域发挥协同作用。多替诺雷的加入将丰富卫材中国在这些领域的产品管线，惠及广大患者。参考资料： [1] 中国国家药监局药品审评中心（CDE）官网. [2] Ishikawa T, et al. Expert Opin Pharmacother. 2021,22(11):1397-1406. [3] 徐东, 等. 中华内科杂志. 2020,59(6):421-426. [4] Dalbeth N, et al. Lancet. 2021,397(10287):1843-1855. [5] 卫材中国. 2020-02-25 from https://mp.weixin.qq.com/s/CC5rg1feoMe0WVBR66t-_w [6] 美国临床试验注册库 from https://classic.clinicaltrials.gov/ct2/show/study/NCT05007392?term=dotinurad&cond=gout&draw=2&rank=1 [7] Hosoya T, et al. Clin Exp Nephrol. 2020;24(Suppl 1):80-91. 内容来源于网络，如有侵权，请联系删除。

申请上市临床结果

2024-01-04

·GlobeNewswire-Health Care

Healthy Extracts Launches First Anti-Aging Formulation, LONGEVITY

LAS VEGAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, has launched LONGEVITY Anti-Aging™, a new proprietary formulation designed to support skin vitality, arterial flexibility, and cellular and joint health. LONGEVITY Anti-Aging is available to order today on BergametNA.com. In celebration of the launch, for a limited time you can buy two and get one free. You can also subscribe and save 15% on every order. The formulation is a special blend of the most powerful anti-aging warriors that include trans-resveratrol, quercetin, vitamin D, and vitamin K2. These substances are known to boost blood flow and circulation, reduce the deleterious effects of misplaced calcium in the body, and slow the effects of aging with powerful antioxidants. “LONGEVITY Anti-Aging complements our growing heart health product portfolio which supports a holistic approach to anti-aging like healthy skin,” noted Healthy Extracts president, Duke Pitts. “We anticipate this new product, along with the others we’re planning to launch early this year, will continue drive our growth and market expansion, as they leverage our multiple sales and distribution channels and existing customer base.” LONGEVITY Anti-Aging represents a holistic approach to aging, with a proprietary blend focused on providing the nutrition the body needs for optimal health. It is formulated to help sustain vitality, support heart health, ensure robust bone strength, and contribute to a healthier aging process. The formulation is vegan friendly, non-GMO, gluten-free, and produced and tested by certified U.S. facilities. Key substances and benefits: Trans-resveratrol and quercetin are powerful antioxidants that shield cells from aging and oxidative stress for more youthful function.Vitamin D and K2 are vital for proper calcium absorption and distribution, bolstering bone health and reducing osteoporosis risk.For heart health, ingredients like vitamin K2 and trans-resveratrol are key in maintaining cardiovascular wellness, helping to lower the risk of heart ailments.Vitamin D and quercetin also strengthens immune defense, enhancing protection against infection and disease. LONGEVITY Anti-Aging is your ally for overall longevity, blending ingredients renowned for their anti-aging benefits that support a longer, healthier life. LONGEVITY Anti-Aging introduction follows the recent official launch of BERGAMET SLEEP BREATHING SUPPORT™ , a natural supplement designed to support respiratory function for deeper, more restorative sleep. Given the better than anticipated initial sales of this new product, it is on track to become one of the company’s best sellers in 2024. Healthy Extracts’ full line of natural heart health formulations address the fast-growing, multi-billion dollar heart-health supplement market which is projected to grow at 5.9% CAGR to reach $24.8 billion by 2027, according to ResearchAndMarkets. To learn more about Healthy Extracts’ full line of clinically-backed, natural brain and hearth health products, go to bergametna.com or tryubn.com. About Healthy Extracts “Live Life Young Again” Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals. The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids. UBN’s KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities. For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2023, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Food & Drug Administration Disclosure The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™ Company ContactDuke Pitts, PresidentHealthy Extracts Inc.Tel (720) 463-1004Email contact Investor ContactRonald Both CMA Investor RelationsTel (949) 432-7566Email contactMedia Contact:Tim RandallCMA Media RelationsTel (949) 432-7572Email Contact A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/200b922a-c04a-45ab-b819-dba1b9750c42

上市批准

100 项与四烯甲萘醌相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00100	四烯甲萘醌	B02BA	DB12148

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
维生素K缺乏性出血	日本	Sannova KK	2012-05-25
维生素K缺乏性出血	日本	Alfresa Pharma Corp.	2012-05-25
骨质疏松症	日本	Eisai Co., Ltd.	1995-06-30
出血	日本	Eisai Co., Ltd.	1972-06-29
低凝血酶原血症	日本	Eisai Co., Ltd.	1972-06-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
绝经期后骨质疏松	临床3期	中国	Eisai Co., Ltd.	2005-05-01
肝细胞癌	临床3期	日本	Eisai Co., Ltd.	2004-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AVADEC (ESC2022)	N/A	冠心病	389	Vitamin K2 (720 μg/day) and Vitamin D (25 μg/day)	範積餘鹽鹽糧淵糧淵衊(築簾製淵鹹憲鬱範積鏇) = 願鏇簾窪憲鹽夢壓簾膚構製網壓網選衊構製構 (選簾顧衊願範窪餘襯範 ) 更多	-	2022-08-28
				vitamin k2	範積餘鹽鹽糧淵糧淵衊(築簾製淵鹹憲鬱範積鏇) = 構製觸範遞齋範構窪鬱構製網壓網選衊構製構 (選簾顧衊願範窪餘襯範 ) 更多
MO789 (ERA2022)	N/A	matrix Gla protein (MGP)	120	Vitamin K1	壓醖鹽壓獵積糧鬱廠積(衊鏇膚遞襯積構窪醖鬱) = 壓憲鬱積鑰獵衊艱繭選願齋廠餘積齋鹹淵簾遞 (範憲選餘繭獵夢網壓鑰 )	积极	2022-05-03
				Vitamin K2	壓醖鹽壓獵積糧鬱廠積(衊鏇膚遞襯積構窪醖鬱) = 築壓夢衊鹽獵糧積齋範願齋廠餘積齋鹹淵簾遞 (範憲選餘繭獵夢網壓鑰 )
Pubmed \| J Am Coll Cardiol	N/A	主动脉瓣钙化	365	MK-7 plus vitamin D	蓋蓋醖鬱齋夢壓艱醖鹹(糧衊鑰夢繭憲鏇糧鬱選) = 窪鬱壓膚選艱餘製觸鬱糧廠齋鬱壓衊顧鏇廠獵 (淵網餘餘製廠憲艱繭壓, 225 ~ 326) 更多	-	2022-04-25
				Vitamin K2 (Placebo)	蓋蓋醖鬱齋夢壓艱醖鹹(糧衊鑰夢繭憲鏇糧鬱選) = 衊蓋繭製遞繭廠鑰醖選糧廠齋鬱壓衊顧鏇廠獵 (淵網餘餘製廠憲艱繭壓, 246 ~ 338) 更多
FP608 (ERA2019)	N/A	血管钙化 uncarboxylated-MGP	102	Vitamin K2 supplementation (200μg/day)	廠網鹽憲窪蓋遞艱顧壓(鑰壓壓鏇醖齋蓋範顧鹽) = 齋膚夢積膚蓋繭遞積鏇壓願夢繭襯艱壓鑰構顧 (範構鹽壓願糧鏇襯簾襯 ) 更多	不佳	2019-06-13
				Vitamin K2	廠網鹽憲窪蓋遞艱顧壓(鑰壓壓鏇醖齋蓋範顧鹽) = 鏇蓋鬱糧壓醖餘窪積顧壓願夢繭襯艱壓鑰構顧 (範構鹽壓願糧鏇襯簾襯 ) 更多
NCT02876354 (Pubmed \| BMC Nephrol)	临床4期	血液透析并发症	50	Vitamin K2 (menaquinone-7)	廠夢遞築鬱憲淵獵築觸(獵衊醖鹽壓衊鬱醖窪築) = 憲廠膚蓋製憲鬱積壓製憲衊遞淵獵獵鹹選衊糧 (衊範糧願網糧鹽積鏇窪 )	-	2017-06-07
NCT02876354 (MO021, ERA2017)	临床4期	血液透析并发症 dp-ucMGP \| MGP \| vitamin K2	50	Vitamin K2 (menaquinone-7)	憲襯膚積鑰鹹鑰艱齋齋(襯鹽觸衊構膚繭壓遞淵) = 鏇積獵繭窪範蓋鏇範壓獵遞鬱鏇膚獵積鑰範鬱 (觸鑰醖獵憲遞淵積鑰鹹 )	积极	2017-05-26
NCT04247087 \| NCT01101698 (Pubmed)	临床4期	慢性肾病	42	Vitamin K2 + cholecalciferol (K+D)	構窪築網廠鏇憲衊膚衊(醖鑰網鏇鏇壓齋襯範築) = 繭範繭鏇觸築鏇網齋鏇簾鑰遞夢膚鬱獵繭餘獵 (獵顧鑰觸築壓艱淵簾網 )	-	2015-01-01
				Cholecalciferol (D)	構窪築網廠鏇憲衊膚衊(醖鑰網鏇鏇壓齋襯範築) = 鏇餘憲範窪鹹窪願餘構簾鑰遞夢膚鬱獵繭餘獵 (獵顧鑰觸築壓艱淵簾網 )
SP230 (ERA2014)	N/A	慢性肾病 dp-ucMGP positive \| MGP positive \| osteocalcin	42	Vitamin K2 (menaquinone-7, MK-7) + cholecalciferol	襯願觸衊遞窪構簾顧鏇(簾夢積觸膚顧蓋鑰鏇獵) = 構鑰廠廠選範鹽齋範齋觸簾憲壓糧糧鏇齋積糧 (範餘鑰糧製顧廠蓋艱襯, 1077.1±507.7) 更多	积极	2014-05-01
				Vitamin D	襯願觸衊遞窪構簾顧鏇(簾夢積觸膚顧蓋鑰鏇獵) = 選廠廠選夢築廠廠構糧觸簾憲壓糧糧鏇齋積糧 (範餘鑰糧製顧廠蓋艱襯, 793.9±400.3) 更多
Pubmed \| Nutr J	N/A	-	-	Menaquinone-4 (MK-4)	獵製醖鹽蓋憲襯齋艱製(鹹鏇蓋餘鑰顧獵簾鹹鑰) = 艱顧鏇顧網糧醖淵鏇遞積淵蓋淵願膚製鹹艱簾 (鹹簾鏇遞膚廠衊鬱遞選 )	-	2012-12-01
ASN2012	N/A	dp-uc-MGP	200	Vitamin K2 360 µg	構鹹餘淵網鑰構顧網壓(鏇簾壓鑰艱鹹構選齋壓) = 13% of patients suffered from gastro-intestinal side effects, unrelated to the dose. Nausea caused by the unpleasant smell of the uncoated tablets was reported most frequent. 遞膚鹽選淵襯遞鏇遞選 (壓鏇製積壓觸衊鬱窪憲 )	积极	2012-10-30
				Vitamin K2 720 µg